Variation in use of menopausal hormone treatment on risk of health outcomes

Table 2 Menopausal hormone treatment and risk of serious outcomes: Ever-use, timing of initiation of treatment and type of regimen

	Relative risk estimate (95%Cl)
	Coronaryartery disease	Stroke	Peripheralartery disease	Breastcancer
Ever-use	1.29 (0.76, 2.20)	1.14 (0.61, 2.14)	2.16 (0.99, 4.71)	0.84 (0.40, 1.76)
	P = 0.35	P = 0.69	P = 0.051	P = 0.65
Timing of initiation from onset of menopause
Early start	1.02 (0.56, 1.86)	1.04 (0.52, 2.06)	1.65 (0.69, 3.94)	0.97 (0.45, 2.08)
	P = 0.94	P = 0.92	P = 0.26	P = 0.94
Late start	2.57 (1.15, 5.72)	1.57 (0.56, 4.37)	4.42 (1.55, 12.64)	0.34 (0.05, 2.37)
	P = 0.021	P = 0.39	P = 0.0052	P = 0.28
Type of regimen
Oestrogen only	2.34 (0.93, 5.88)	0.78 (0.18, 3.49)	5.01 (1.62, 15.48)	2.05 (0.65, 6.46)
	P = 0.07	P = 0.75	P = 0.005	P = 0.22
Oestrogen + progestogen	1.16 (0.65, 2.06)	1.23 (0.64, 2.37)	1.59 (0.67, 3.79)	0.67 (0.29, 1.55)
	P = 0.62	P = 0.53	P = 0.30	P = 0.35
Combination of treatment strategy
Early start plus oestrogen-only	2.57 (0.88, 7.52)	1.22 (0.27, 5.56)	1.32 (0.16, 10.78)	2.36 (0.64, 8.72)
	P = 0.09	P = 0.80	P = 0.80	P = 0.20
Early start plus oestrogen + progestogen	0.86 (0.44, 1.66)	1.03 (0.50, 2.12)	1.72 (0.70, 4.26)	0.81 (0.35, 1.89)
	P = 0.65	P = 0.94	P = 0.24	P = 0.62
Late start plus oestrogen-only	1.92 (0.39, 9.45)	NC	16.73 (4.12, 67.91)	1.48 (0.18, 12.29)
	P = 0.42		P < 0.0012	P = 0.71
Late start plus oestrogen + progestogen	3.08 (1.26, 7.55)	2.38 (0.83, 6.83)	0.93 (0.12, 7.46)	NC
	P = 0.011	P = 0.11	P = 0.94

NC: No convergence due to small numbers. By multivariate analysis adjusting for age at recruitment, body mass index, smoking, physical activity and alcohol use, co-morbidities (diabetes mellitus, hypertension, hypercholesterolaemia) shows:

¹P 0.05 – 0.01;

²P < 0.01.